Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 71 for “"neoadjuvant therapy"”.
-
Response assessment after neoadjuvant therapy in esophageal cancer : towards personalized treatment
Contains fulltext : 230646.pdf (Publisher’s version ) (Open Access)
-
Artificial intelligence in monitoring response to neoadjuvant therapy for breast cancer
Contains fulltext : 329216.pdf (Publisher’s version ) (Closed access)
-
Automatic Cellularity Assessment in Surgical Specimens After Neoadjuvant Therapy of Breast Cancer
… tumor cellularity in surgical specimens after neoadjuvant chemotherapy for breast cancer. At present pathological examination of the tissue sections after surgery is the gold-standard to estimate the residual tumor. Currently, tumor cellularity is manually estimated by pathologists from …
-
Economic Evaluation of Total Neoadjuvant Therapy and Watch and Wait in Rectal Cancer
… and multi-modal treatments such as radiotherapy, chemotherapy, and surgery. Despite these treatments and often very morbid surgeries, traditional management still results in high rates of distant metastasis, which directly impacts patient survival prospects and quality of life (QoL), and …
-
Prediction of Pre-Operative Local Staging and Optimising Treatment Response to Neoadjuvant Therapy in Colorectal Cancer.
… about the risk vs benefit of chemotherapy can be made reliably. Patients with advanced rectal cancer are commonly referred for neoadjuvant therapy as part of standard care treatment protocols based on Magnetic Resonance Imaging (MRI) local staging. Following neoadjuvant therapy, …
-
The Performance of Circulating Biomarkers in the Prediction of Response to Neoadjuvant Therapy in Patients with Oesophago-gastric Cancer
… beyond 5 years after diagnosis. The addition of neoadjuvant therapy has been shown to increase survival in patients suitable for curative surgery. However, the additional gains are modest and the majority of patients do not respond sufficiently from therapy to gain any benefit. There is an urgent …
-
The use of prognostic factors to identify the group of beneficiaries for secondary resection in patients with primarily not-resectable pancreatic adenocarcinoma
… patients regularly receive palliative chemotherapy. However, current studies show a benefit of neoadjuvant intended therapy and subsequent secondary resection for some patients. This investigation aimed to find factors that help identify patients with a good prognosis to justify an …
-
Statistical Approaches to Identifying Therapeutic Vulnerabilities from Cancer Genomics Data
… of cancers due to cancer cells’ resistance to therapy. There is a significant challenge in identifying which patients will benefit from targeted therapies and matching the correct therapy to each patient. This demonstrates the need for a comprehensive statistical analysis of genomic alterations …
-
Tumor- und risikoadaptierte Individualisierung der neoadjuvanten und post-neoadjuvanten Therapie bei PatientInnen mit Mammakarzinom
… decade, modern oncology has switched from a “one therapy fits all” to a risk-tailored and individualized medicine. For breast cancer, the most common malignancy in women worldwide, this has led to early breast cancer nowadays being seen as a curable disease. A great benefit of modern diagnostic …
-
Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer
… of patients with oesophageal cancer undergoing neoadjuvant therapy. METHODS: Results of pathological staging were correlated with those from 64-MDCT before and after neoadjuvant treatment in 35 patients using the American Joint Committee on Cancer/TNM classification (7th edition). CT response …
-
Phenotypic dynamics of rectal cancer under neoadjuvant therapy: a multi-omic single-cell perspective from patient-derived organoids [Evoluzione fenotipica del carcinoma del retto durante terapia neoadiuvante: una prospettiva multi-omica a singola cellula da organoidi derivati dal paziente]
Questo studio esplora i meccanismi di adattamento fenotipico e l’eterogeneità intratumorale (ITH) nel carcinoma colorettale, con particolare attenzione alle forme localmente avanzate di carcinoma del retto. La resistenza terapeutica rappresenta una delle principali sfide in oncologia; comprenderne …
-
Longitudinal T cell receptor repertoire analysis in immunotherapy of HER2-positive breast cancer
… the receptor HER2, are treated using neoadjuvant immunochemotherapy containing anti-HER2 antibodies. T cells are immune cells identified by a T cell receptor, which is capable of highly specific binding to antigenic peptides presented by major histocompatibility complex proteins, and …
-
Enhancing the neoadjuvant treatment of rectal cancer by targeting the Inhibitor of Apoptosis Proteins
Total neoadjuvant therapy (TNT) has emerged as a standard approach for locally advanced rectal cancer, combining (chemo)radiation and systemic chemotherapy prior to surgery. This strategy improves tumour downstaging, increasing the likelihood of non-operative management, and reduces local and …
-
Outcomes Following Resection for Esophageal Cancer in Ontario
… patients at thoracic centres received more neoadjuvant therapy, had similar margin rates and lymph node harvest, experienced lower postoperative mortality, and had similar overall survival. Across thoracic centres, neoadjuvant therapy use varied from 16.4-81.6%, positive margin rates varied …
-
Unveiling the Molecular Features of Cancer Health Differences Through Multi-Omics Data Analysis
… between complete and incomplete responders to Neoadjuvant therapy in rectal cancer. In chapter 2, the content focuses on investigating the molecular characterizations of 14 cancer types with different body fat. We identify molecular alterations and pathways associated with overweight/obesity …
-
RNA HELICASE, DP103 AS A PREDICTIVE BIOMARKER FOR DOCETAXEL RESPONSE IN ERa-POSITIVE BREAST CANCER
… PHASE II STUDY INVOLVING DOCETAXEL BASED NEOADJUVANT THERAPY, CLINICAL RESPONDERS WERE CHARACTERIZED BY A PROGRESSIVE DECREASE IN DP103 EXPRESSION. THIS DECREASE IN DP103 EXPRESSION WAS ONLY OBSERVED IN RESPONDERS WITH ERA-POSITIVE STATUS AND NOT ERA-NEGATIVE STATUS. DEPLETION OF DP103 …
-
Refining tumor response in rectal cancer: the role of tumor budding
… innovative approaches to evaluate response to neoadjuvant therapy in colorectal cancer, focusing on tumor budding (TB) as a predictive biomarker. We examined TB and tumor-infiltrating lymphocytes (TILs) as opposing forces in the tumor microenvironment, emphasizing their prognostic significance. …
-
A Convolutional Neural Network Approach to Breast Cancer Tumor Boundary Detection
… diagnosed with breast cancer and undergoing neoadjuvant therapy. For training, image masks were generated as ground truths using signal enhancement ratio segmentation, thresholding, and contour detection. The effectiveness of two lightweight models, with and without batch normalization and …
Page 1 of 4